Nasdaq

Fortress Biotech and Helocyte Launch Phase 2 Trial for CMV Vaccine Triplex in Stem Cell Transplant Recipients

Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
Nasdaq

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the ...
Business Wire

Triplex Meets Primary Endpoint in Phase 2 Clinical Trial, Reduces Rate of Cytomegalovirus (CMV) Complications in Transplant Recipients by 50 Percent

First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem cell transplant recipients DUARTE, Calif.--(BUSINESS WIRE)--City ...